These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 10941908)

  • 1. Therapeutic potential of chimeric anti-(ganglioside GD3) antibody KM871: antitumor activity in xenograft model of melanoma and effector function analysis.
    Kanazawa J; Ohta S; Shitara K; Fujita F; Fujita M; Hanai N; Akinaga S; Okabe M
    Cancer Immunol Immunother; 2000 Jul; 49(4-5):253-8. PubMed ID: 10941908
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Specific localization, gamma camera imaging, and intracellular trafficking of radiolabelled chimeric anti-G(D3) ganglioside monoclonal antibody KM871 in SK-MEL-28 melanoma xenografts.
    Lee FT; Rigopoulos A; Hall C; Clarke K; Cody SH; Smyth FE; Liu Z; Brechbiel MW; Hanai N; Nice EC; Catimel B; Burgess AW; Welt S; Ritter G; Old LJ; Scott AM
    Cancer Res; 2001 Jun; 61(11):4474-82. PubMed ID: 11389078
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A mouse/human chimeric anti-(ganglioside GD3) antibody with enhanced antitumor activities.
    Shitara K; Kuwana Y; Nakamura K; Tokutake Y; Ohta S; Miyaji H; Hasegawa M; Hanai N
    Cancer Immunol Immunother; 1993 Jun; 36(6):373-80. PubMed ID: 8500110
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cytokine enhancement of in vitro antibody-dependent cellular cytotoxicity mediated by chimeric anti-GD3 monoclonal antibody KM871.
    Liu Z; Lee FT; Hanai N; Smyth FE; Burgess AW; Old LJ; Scott AM
    Cancer Immun; 2002 Oct; 2():13. PubMed ID: 12747758
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Recombinant antibodies against ganglioside expressed on tumor cells.
    Hanai N; Nakamura K; Shitara K
    Cancer Chemother Pharmacol; 2000; 46 Suppl():S13-7. PubMed ID: 10950141
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antitumor effects of a novel monoclonal antibody with high binding affinity to ganglioside GD3.
    Ohta S; Honda A; Tokutake Y; Yoshida H; Hanai N
    Cancer Immunol Immunother; 1993; 36(4):260-6. PubMed ID: 8439988
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Anti-GD3 chimeric sFv-CD28/T-cell receptor zeta designer T cells for treatment of metastatic melanoma and other neuroectodermal tumors.
    Lo AS; Ma Q; Liu DL; Junghans RP
    Clin Cancer Res; 2010 May; 16(10):2769-80. PubMed ID: 20460472
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunological effects of chimeric anti-GD3 monoclonal antibody KM871 in patients with metastatic melanoma.
    Scott AM; Liu Z; Murone C; Johns TG; MacGregor D; Smyth FE; Lee FT; Cebon J; Davis ID; Hopkins W; Mountain AJ; Rigopoulos A; Hanai N; Old LJ
    Cancer Immun; 2005 Feb; 5():3. PubMed ID: 15723450
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immune and nonimmune effector functions of IgG3 mouse monoclonal antibody R24 detecting the disialoganglioside GD3 on the surface of melanoma cells.
    Welt S; Carswell EA; Vogel CW; Oettgen HF; Old LJ
    Clin Immunol Immunopathol; 1987 Nov; 45(2):214-29. PubMed ID: 3665201
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Strong antitumor activities of IgG3 antibodies to a human melanoma-associated ganglioside.
    Hellström I; Brankovan V; Hellström KE
    Proc Natl Acad Sci U S A; 1985 Mar; 82(5):1499-502. PubMed ID: 3856277
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Specific targeting, biodistribution, and lack of immunogenicity of chimeric anti-GD3 monoclonal antibody KM871 in patients with metastatic melanoma: results of a phase I trial.
    Scott AM; Lee FT; Hopkins W; Cebon JS; Wheatley JM; Liu Z; Smyth FE; Murone C; Sturrock S; MacGregor D; Hanai N; Inoue K; Yamasaki M; Brechbiel MW; Davis ID; Murphy R; Hannah A; Lim-Joon M; Chan T; Chong G; Ritter G; Hoffman EW; Burgess AW; Old LJ
    J Clin Oncol; 2001 Oct; 19(19):3976-87. PubMed ID: 11579119
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Light chain variants of an IgG3 anti-GD3 monoclonal antibody and the relationship among avidity, effector functions, tumor targeting, and antitumor activity.
    Chapman PB; Lonberg M; Houghton AN
    Cancer Res; 1990 Mar; 50(5):1503-9. PubMed ID: 2105840
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Construction of humanized anti-ganglioside monoclonal antibodies with potent immune effector functions.
    Nakamura K; Tanaka Y; Shitara K; Hanai N
    Cancer Immunol Immunother; 2001 Jul; 50(5):275-84. PubMed ID: 11499811
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Activation of cellular cytotoxicity and complement-mediated lysis of melanoma and neuroblastoma cells in vitro by murine antiganglioside antibodies MB 3.6 and 14.G2a.
    Mayer P; Handgretinger R; Bruchelt G; Schaber B; Rassner G; Fierlbeck G
    Melanoma Res; 1994 Apr; 4(2):101-6. PubMed ID: 8069095
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Enhancement of antibody-dependent cytotoxicity with a chimeric anti-GD2 antibody.
    Mueller BM; Romerdahl CA; Gillies SD; Reisfeld RA
    J Immunol; 1990 Feb; 144(4):1382-6. PubMed ID: 2303711
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Chimeric anti-ganglioside GM2 antibody with antitumor activity.
    Nakamura K; Koike M; Shitara K; Kuwana Y; Kiuragi K; Igarashi S; Hasegawa M; Hanai N
    Cancer Res; 1994 Mar; 54(6):1511-6. PubMed ID: 8137257
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Biodistribution study of murine monoclonal anti-GD3 antibody in nude mice bearing human melanoma xenografts for development of immunoscintigraphy.
    Ojima F; Ido T; Kijima-Suda I; Nakagawa Y
    Tohoku J Exp Med; 1998 Jun; 185(2):89-100. PubMed ID: 9747648
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Monoclonal antibodies to disialogangliosides: characterization of antibody-mediated cytotoxicity against human melanoma and neuroblastoma cells in vitro.
    Kawashima I; Tada N; Fujimori T; Tai T
    J Biochem; 1990 Jul; 108(1):109-15. PubMed ID: 2121721
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The idiotype (Id) cascade in mice elicited the production of anti-R24 Id and anti-anti-Id monoclonal antibodies with antitumor and protective activity against human melanoma.
    Ramos AS; Parise CB; Travassos LR; Han SW; de Campos-Lima PO; de Moraes JZ
    Cancer Sci; 2011 Jan; 102(1):64-70. PubMed ID: 21070480
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Expansion of natural killer cells in mice transgenic for IgM antibody to ganglioside GD2: demonstration of prolonged survival after challenge with syngeneic tumor cells.
    Kawashima I; Yoshida Y; Taya C; Shitara H; Yonekawa H; Karasuyama H; Tada N; Furukawa K; Tai T
    Int J Oncol; 2003 Aug; 23(2):381-8. PubMed ID: 12851687
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.